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T reatment of normal primary human keratinocytes with 
phorbol 12-myristate 13-acetate (PMA) or phorbol 12-13 
dibu tyrate (PDBu) (100 ng/ml , 6- 40 h) followed by two-
dimensional (2-D) gel electrophoresis (isoelectric focusing) 
and microsequencing identified three polypeptides (phorbo-
lin 1, Mr = 19.9 kDa; phorbolin 2, Mr = 19.7 kDa; and 
interleukin- l (IL-l) receptor antagonist, IL-1ra, Mr = 19.5 
kDa) that are upregulated eight times or more by the phorbol 
esters and that are highly expressed in noncultured psoriatic 
keratinocytes . T he response w as not elicited by other ef-
fectors tested including second messengers (Bt2cAMP, 
Psoriasis is a hyperproliferative disease that affects about 3% of th e population in industrialized countries and th at is characterized by abnormal cell proliferation and dif-fe rentiation as well as by inflammation ([1 - 3] and refer-ences therein) . The etiology of the disease is at present 
unknown although there have been reports indicating that protein 
kinase C (PKC) may play a ro le in the pathophysiology of the 
disease [4 - 6] and that PKC inhibitors may have therapeutic benefits 
[7 - 9]. 
In this laboratory, we have established a comprehensive two-
dimensional (2-D) gel database of normal human keratinocyte pro-
te ins for the study of cell proliferation, differentiation, and skin 
diseases, cancer incl uded [10,11]. Currently , the database lists 2980 
cellular proteins, of which about 20% have been identified [11] . 
T he aim of establishing such a database is to gather, throu gh a 
systematic study of these cells, qualitative and quantitative informa-
tion on keratinocyte proteins that may allow us to identify abnormal 
patterns of gene expression and ultimately to pinpoint signaling 
pathways and components th at are affected in various skin diseases. 
H ere we report the identification of th ree proteins (phorbolins 1 
and 2 and IL-l receptor antagonist [IL-lra]) that are strongly upre-
gulated by treatment of normal primary human keratinocytes with 
phorbol 12-myristate 13-acetate (PMA) or phorbol 12-13 dibutyr-
ate (PBD u) and that are highly expressed in noncultured psoriatic 
keratin ocytes ([10 - 14]' this study). 
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Bt2cGMP), cytokines (basic fibroblast growth factor, trans-
forming growth factor-a , IGF-II , tumor necrosis factor-a, 
and -p, interleukin (IL)-la, IL- 1P, IL-2, IL-3 , IL-6 , IL-7, 
IL-8, interferon-a, and -y), and other substances (Ca++, dex-
ametasone, retinoic acid , lipopolysaccharides) and it w as par-
tially reversed by staurosporine, a strong inhibitor of protein 
kinase C. The results are taken to imply that the protein 
kinase C signaling pathway may be altered in psoriatic kera-
tinocytes. Key words: psoriasis/protein kinase C /staurospor-
ine. ] Invest D ermatol101 :560-566, 1993 
MATERIALS AND MET HODS 
Noneultured Unfractionated Human Keratinocytes Strips of normal 
and psoriatic skin (dermatome shav ing) obtained from Aarhus Kommune-
hospital were was hed three times in Hanks' buffered saline solution (HESS; 
400 mg KC I, 60 mg KH2PO. , S g NaCI, and 47 .5 mg Na2HPO. per liter) 
and placed in 0.25% trypsin in HBSS at 4 ' C fo r at least 24 h. Following 
incubation, the stri ps were was hed three times in serum-free keratinocyte 
medium (SFK.M) (GIBCO ) containing antibiotics (penicillin, 100 U /mJ; 
streptomycin, 50 jig/ml; Biochrom KG, Germany) , epidermal growth 
factor (EGF, 5 ng/ml), and bovine pituitary extract (BPE, 50 jig/mJ). 
The epidermis was then detached fro m the dermis and resuspended in the 
same medium. Normal and psoriatic keratinocytes were detached by vigor-
ous shaking, washed two to three times, and resuspended in the same me-
dium. 
Primary Normal Human Keratinocytes Normal unfractionated ker.t-
tinocytes prepared as described above were plated in 3-cm Petri dishes coated 
with a human dermal extract and containing 3 ml of SFK.M supplemented 
with antibiotics (penicillin 100 U / ml; streptomycin, 50 jig/ml; Biochrom 
KG , Germany), EGF (5 ng/ml), and EPE (50 jig/ml). 
Preparation of Human Dermal Extracts Strips of normal skin washed 
as described were placed in HBSS containing 1 M N aCI for 72 hat 4 'CO The 
epidermis was then peeled off and the dermis washed twice in HESS. There-
after, the dermis was homogenized in the same buffe r and the soluble extr.tct 
was recovered by centrifugation. The ex tract was then dialyzed against 
HESS, filter sterili zed, and stored at 4 ' C. Pe tri dishes were coated with the 
extract overnight at 4 ' C (20 Jlg/ml) . The extract was then aspirated and the 
plates kept at 4 ' C until usc. 
[ 35S]-Methionine Labeling of Keratinoeytes in SFKM Unfraction_ 
ated normal and psoriatic keratinocytes were labeled for 20 h in SFKM 
lacking methionine (prepared by GIBCO) and containing 50 jiC i of 
[35S]-methionine (SJ 204, Amersham) per 0 .1 ml of medium. At the end of 
the labeling period the cells were recovered by centri fugation and resus-
pended in lysis so lution [15]. Primary keratinocyte cultures in 3-cm Petri 
dishes were labeled for various periods of time (see legend to T able III) ill 
1 ml of SFK.M lacking methionine and containing 400 jiC i of[35S]-methio_ 
nine. Petri dishes were covered with Saran Wrap during incubation. Fol-
lowing labeling, the medium was aspirated and the ce lls resuspended in lysis 
solution [1 5). 
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FigUre 1. JEF 2-D gel patterns of [3SS]~methionine- labeled proteins from (A) normal unfractionated human keratinocytes and (B) .psoriatic unfractionated 
human keratmocytes. Normal and psonatlc u~fractlOnated, noncultured ker~tll1ocytes were labeled for 20 h 111 SFKM as descnbed 111 Materials alld Met/rods. 
Proteins highly upr.eg~lated In psonatlc kerat1110cytes are mdlcated With their name and/or number 111 the keratinocyte 2-D gel protein database [11]. The 
position of actll1 IS mdlcated fot reference. 
Table I. [35SJ-Methionine-Labeled Proteins Highly Upregulated in Noncultured Unfractionated Psoriatic 
Keratinocytes and PMA-Treated Normal Cultured Keratinocytes 
Proteins Highly 
Molecular Upregulated in 
psoriatic Keratinocytes' Mass 
(rEF SSP Number) (kDa) pI 
1003 9.3 7.11 
2006 17.5 6.52 
2116 19.9 6.60 
2209 39.5 6.58 
3002 11.0 6.21 
3007 12.4 6.35 
3210 40.9 6.31 
4003 11.3 5.89 
4205 40.1 5.96 
4326 40.3 5.87 
5007 11.7 5.77 
6010 11.6 5.43 
6011 11.2 5.27 
6016 12.1 5.29 
6017 12.5 5.87 
6511 64.3 5.47 
7013 11.7 5.13 
7105 19.5 4.99 
7112 28.9 4.96 
7216 34.7 4.97 
7430 48 .3 4.85 
7431 48.1 4.74 
8012 17.1 4.78 
8216 39.4 4.90 
Identity' 
MRP 8, calgranulin A 
Phorbolin 2 
Phorbolin 1 
Unknown 
Psoriasin 
Homologous to fatty acid 
binding proteins (PA-FA13P) 
Unknown 
Unknown 
Unknown 
Unknown 
MRP 14, calgranulin B, Ll , 
calprotectin 
MRP 14, calgranulin B, Ll , 
calprotectin 
Cystatin A, stelin A 
MRP 14, calgranulin B, Ll, 
calprotectin 
MRP 14, calgranulin B, Ll , 
ca lprotectin 
hsx 70 
MRP 14, ca lgranulin B, Ll, 
calprotcctin 
InterIeukin-l receptor antagonist 
(IL-lra) 
Unknown 
Unknown 
Keratin 16 
Keratin 16 phosphorylated variant 
Unknown 
Unknown 
Proteins U preglliated 3 X 
or More in Normal 
Cultured Keratinocytes 
Treated with PMA 
(Ratio PMA-Treated versus Contro l) 
8.2 
11.2 
5.9 
3.9 
3.4 
PMA-Induced Proteins 
that are Upreglliated in 
Abnormal Differentiated 
Cultured Keratinocytes' 
+ 
nd' 
+ 
+ 
+ 
+ 
• Noncultured, unfractionated normal and psoriatic keratinocytes prepared as described in Materials atld Methods were labeled with ["SI-methionine for 20 h (sec also [12,14]) . 
• Partly taken from [13,14]. 
, Normal primary cultured keratinocytes prepared as described in Marerials alld Methods were treated for 20 h with PMA (100 ng/ml) , 5 d after plating the cultures in 3-cm Petri 
dishes. PMA-treated cells were labeled for 20 h with ["S1-methionine in the presence ofPMA. Control cells treated with equivalent amounts of OM SO used to dissolve the PMA 
were labeled for the same length of time in the presence of OM SO. At the end of the labeling period the cells were recovered by centrifugation, resuspended in lysis solution [1 5], and 
run in IEF 2-D gels. Radioactive proteins were cut from the dry IEF gels with the help of an X-ray film and placed in scintillation vials containing 4 ml of Filter-count (Packard) and 
counted for 5 min in a LKB 1209 Rackbeta liquid scintillation counter. The radioactivity was normalized to the total number of counts recovered frolll the gels . 
J nq, not quantitated. The icyc,)s of the protein in control cells is very low. VisuaJ inspection of the gels, however, indicated several times uprcgllla. tio n. 
, nd, not determined. 
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Figure 2. IEF 2-0 gel of[35S)-methionine- labeled proteins from (A) normal primary human kera tinocytes and (B) PMA-trea ted normal primary human 
keratinocytes. Normal cultured primary keratinocytes were treated for 20 h with PMA (100 ng/ml) 5 d after plating the cultures in 3-cm Petri dishes. 
Thereafter, they were labeled for 20 h with ["S)-methionine, as described in Materials o"d Methods, in the presence ofPMA. Controls were labeled for the same 
length of time in the absence of PMA but containing equivalent amounts of OMSO used to dissolve the PMA. Samples were ana lyzed by IEF 2-0 gel 
electrophoresis fo llowed by autoradiography. Only proteins upregulated by PMA that are relevant to this study are indicated with their names and/or their 
numbers in the keratinocyte 2-0 gel pattern database [11) . The position of actin is indicated for reference. 
[3ZP)-Orthophosphate Labeling ofKeratinocytes in SFKM Normal 
primary human keratinocytes prepared as described above were treated with 
PMA (100 ng/rn l) for 20 h and labeled for 7 h with [32P)-orthophosphate in 
SFKM lacking phosphate and containing the phorbol ester. Control kerati-
nocytes (treated with cquivalcnt amounts of dimethy lsulfoxide [OMSO) 
used to dissolve the PMA) were labeled for 7 h with [32P)-orthophosphate in 
the presence of OMSO. 
The procedures for 2-0 gel electrophoresis and microsequcncing have 
been dcscribed in detai l elsewhere [15 - 17). 
RESULTS 
Figure 1 shows f1uorograms of isoelectric focusing (IEF) 2-D gels of 
[35SJ-methionine-Iabeled cellular proteins from unfractionated, 
non-cultured human keratinocytes prepared from normal (Fig 1A) 
and psoriatic (Fig lB) skin. Proteins highly upregulated in psoriatic 
keratinocytes [10-14] are indicated in Fig 1 with their name and/or 
their number in the master 2-D gel database ofkeratinocyte proteins 
[10,11] and are listed in Table I together with their coordinates 
[apparent molecular weight (Mr) and pI]. 
Because there is indirect evidence in the literature suggesting that 
the PKe signaling pathway may be hyperactive in psoriasis [4-
6,18,19], we treated normal cultured primary human keratinocytes 
with phorbol esters for various periods of time (2, 6.5, 12, 23, 29 , 
and 40 h) and analyzed the patterns of protein expression by means 
of high-resolution 2-D gel electrophoresis [10,11]. Many changes 
in protein expression could be observed after 6.5 h of treatment but 
only those proteins that are also highly upregulated (three times or 
more) in psoriatic [10 - 14] skin, and therefore relevant to this study, 
are indicated in Fig 2 (compare Fig 2A, control; Fig 2B, PMA 
treated) and in Table 1. Maximum induction of these proteins was 
observed between 23 and 40 h (Fig 2B) after addition of the phorbol 
ester. Several of the PMA- and psoriasis-upregulated polypeptides 
corresponded to known proteins in the keratinocyte database 
(MRP14 or calgranulin B and their variants, Table I) [14] whereas 
only a few were unknown [10,11). Microsequencing of polypep-
tides IEFs 2116 and 7105 (Table II) fo llowed by database searches 
indicated that IEF 2116 is a novel protein and that IEF 7105 corre-
sponds to the IL-l receptor antagonist (IL-1 raj [20 - 22], a protein 
Table II. Microsequences of IEFs 2116 and 7105 
Protein Molecular 
SSP Mass 
Number (kOa) pI 
2116 19.9 6.60 
7105 19.5 4.99 
Sequcnces in 
One-Letter Notation" 
GFL{H)NQA(K) 
' IYOYOPLYK 
(H)AELR 
IWOVNQ 
TFYLR 
NNQLVAGYL 
FAFIR 
XYFQEO 
Residues in 
Identified 
Protein 
40 - 45 
47-51 
52-61 
123 - 127 
171-176 
Protein Name 
in Searched 
Oatabaseb 
Unknown' 
Interleukin-l 
receptor antagonist 
Swissprotr 
Database 
Reference 
illx human 
, Coomassie bri ll iant-b lue-staincd protcins recovered from sevcral IEF 2-0 gels of PMA-treated keratinocytes were microsequenced as described in 
detail in [17) . The amino acid residues arc given in the one- letter notation. X means that no PTH-amino acid could be detected. Amino acids in paren-
theses represent the most probable assignment. 
b The databases used were: Swissprott (releasc 24.0), Mipsx (release 35.0), and Genembl (re lease 34.0). 
, This protein has been termed Phorbolin 1. 
, 
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Table III. Effect of Various Cytokines, Second Messengers, and Other Substances on 
the Radioactive Levels of Phorbolins 1 and 2, IL-l ra, and MRP 14 (IEF 5007) 
Time of Labeling 
with [35S]_ 
Methionine in Radioactive Levels of' 
Time of the Presences 
Treatment of Factor MRP 14 
(rEF 5007)J Factor" Concentration 
Phorbol esters 
100 ng/ ml PMA 
PMA 1001'g/ml 
PDBu 100 ng/ml 
PDBu 100 ng/ ml 
4-a-PDD 100 ng/ml 
4-a-PDD 100 ng/ml 
Second messengers 
5 X 10-6 M Bt2 cAMP 
Bt2 cGMP 2 X 10-
7 M 
Cytokines 
3.2 ng/ml bFGF 
TGF-a 10 ng/ml 
IGF-II 5 ng/ml 
TNF-a 3.3 ng/ml 
TNF-P 5 ng/ml 
IL-la 2.5 ng/ ml 
IL-IP 2.5 ng/ml 
IL-2 200 V/ml 
IL-3 10 ng/ml 
IL-6 200 V/ml 
IL-7 5 ng/ml 
IL-8 I ng/ml 
IFN-a 500 V/ ml 
IFN-y 100 V/ml 
Others 
Ca++ 2XIO- 3M 
Dexamctasone 10- 6 M 
Retinoic ac id 1 X 10- 7 M 
Lipopolysaccharides 1 ,ug/ ml 
(h) (hb) 
20 3 
20 .20 
20 3 
20 20 
20 3 
20 20 
20 9 
20 9 
20 9 
20 16 
20 16 
20 9 
20 16 
20 9 
20 9 
20 16 
20 9 
20 16 
20 9 
20 20 
19 4.5 
19 4.5 
72 16 
20 9 
96 16 
20 16 
Phorbolin 1 
+ 
+ 
+ 
+ 
Phorbolin 2 
+ 
+ 
+ 
+ 
IL-Ira 
+ 
+ 
+ 
+ 
± 
+ 
+ 
+ 
+ 
± 
+ 
+ 
• Primary cultured human keratinocytes prepared as described in Materials alld Methods were treated with the various substances 5 d after plating in SFKM supplemented with EGF 
(5 ng/ml), BPE (35- 50 I'g/ml) , and antibiotics (penicillin, 100 units/ Illl; streptomycin, 50 I'g/ml). 
" Cells were labeled with [35Sj-mcthioninc in the presence of the factors for the times lI1dlcatcd. 
' The level of change of the radioactivity was determined semiquantitativcly by visual inspection of the films. 
, Only the most abundant form of MRP 14 is considered here. 
that is also upregulated by PMA in THP-l cells [23) and that ex-
hibi ts increased activity in psoriatic epidermal cytosol [24). Unfor-
tunately, we have not been able to obtain sufficient amounts ofIEFs 
2006 and 4003 to perform microsequencing. For convenience, we 
have termed IEFs 2116 and 2006 phorbolins 1 and 2, respectively 
(Fig 2; Tables I, III) . 
factor, transforming growth factor-a, IGF-II, tumor necrosis factor 
(TNF)-a, TNF-p, interleukin (IL)-la, IL-1P, IL-2, IL-3 , IL-6, IL-
7, IL-8, interferon (IFN)-a, IFN-P), and compounds known to 
affect keratinocytes (Ca++, dexametasone, retinoic acid, lipopoly-
sacchandes) . A fe~ examples depicting the area of the 2-D gels 
where the phorbolllls 1 and 2 and IL-l ra migrate are shown in Fig 
3e (Bt2cAMP), f (Bt2cGMP), and g (TNF-a) . The results showed 
that none of these agents upregulated phorbolins 1 and 2 or IL-l ra, 
at least for the periods of time tested (Table III). MRP 14 (IEF 
5007)~ on .the other hand, was upregulated by INF-y, IL-l p, and 
retlllOic aCId (Table III). 
DISCUSSION 
As expected, the group of PM A- and psoriasis-upregulated pro-
teins were also induced by phorbol12-13 dibutyrate (PDBu, Fig 3a) 
but not by the inactive analog 4-a-phorbol-12, 13-didecanoate (4-
a -POD, Fig 3b). Furthermore, the effect was substantiall y reversed 
by staurosporine (50 nM, added together with PMA), a strong in-
hibitor of protein kinases [25) (compare Fig 3c [control cells), d). It 
should be noted that staurosporine alone (50 nM, 40 h) produced a 
small but significant induction of the phorbolins, IL- l ra and MRP-
14 and their variants (results not shown), a fact that may explain 
the incomplete reversal of the PMA effect. Contrary to PMA, 
staurosporin did not induce plasminogen activator inhibitor 2 
(PAl-2) (results not shown). These results are in line with published 
studies [26,27) that have shown that staurosporine mimics some 
characteristics of a PKC agonist in keratinocytes. In GH4Cl rat 
, pituitary cells staurosporine causes a selective redistribution of PKC 
isozymes [28). 
To determine whether other effectors were able to induce the 
synthesis of the PMA- and psoriasis-upregulated proteins we tested 
several subs tances listed in Table III . These included second mes-
sengers (Bt2cAMP, Bt2cGMP), cytokines (basic fibrob last growth 
At present, little is known about the function of the PMA- and 
psoriasis-upregulated proteins. IL-l ra is believed to be a natural 
regu lator of IL- l (20), a cytokine ([29,30) and references therein) 
that stimulates the synthesis of inflammatory eicosanoids in macro-
phages, fibroblasts, synovial cells, and chondrocytes [31 ,32)' At least 
two forms of IL-l exist: IL-la and IL-1P, the former being the 
predominant form in resting human keratinocytes [33 - 35). Inter-
estingly, IL-l activity is reduced in psoriatic lesions, a fact that has 
been attributed to the presence of inhibitors [36 ,37]. IL-l ra has 
been shown to be expressed by normal [24,38J and psoriatic kerati-
nocytes [24,39) and is responsible for the majority of th e IL-l in-
hibitor activity present in psoriatic epidermis [24,39). MRP-14 
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Figure J. IEF 2-D gels of[35Sj-methionine-labeled proteins from primary 
cultured keratinocytes treated with various substances: (a) PBOu; (b) 4-a-
POD; (c) PMA; (d) PMA plus staurosporine; (e) Bt2 cAMP; (f) Bt2 cGMP; 
and (g) TNF-a. (h) SV40-transformed keratinocytes (K14) treated with 
PMA. (a, b, and c), cells were treated for 20 h with the phorbol esters (100 
ng/ml) and thereafter labeled for 20 h with l35Sj-methionine in the presence 
of the phorbol esters. Cells in (d) were treated with PMA (100 ng/ml) plus 
staurosporine (50 nM) for 20 h and thereafter labeled for 20 h in the pres-
ence of the substances. Cells in (e, J, and g) were treated with Bt2 cAMP 
(5 X 10- 6 M, 20 h), Bt2cGMP (2 X 10- 7 M,20 h), and TNF-a (3.3 ng/ml, 
20 h), respectively, and thereafter labeled for 9 h in the presence of the 
effectors. SV 40-transformed keratinocytes (K 14) were treated for 20 h with 
PMA (100 ng/ml) and labeled for 20 h with [35Sj-methionine in the pres-
ence of PMA. Samples were analyzed by IEF 2-D gel electrophoresis fo l-
lowed by auto radiography. 
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[40-42], also known as calgranulin B [43]' is a calcium-binding 
protein that is synthesized by ce lls of mye loid origin such as granu-
locytes, monocytes, and macrophages [41,43] and that is expressed 
by infiltrated macrophages during inflammatory reactions [40 ,41]. 
Four variants of this protein have been identified so far and at least 
two are phosphorylated [13,44] (one is indicated with an arrow in 
Fig 4D). The function of this protein is unknown altho ugh it h as 
been implicated in macrophage activation and defense mechanisms 
and there is some indication that it inhibits casein kinase I and 
II [45]. 
The role of the novel proteins phorbolins 1 and 2 is, however, less 
clear. These proteins arc not detected in normal fibroblasts (Fig , 
4A,B) amnion cell s, lymphocytes, melanocytes, sweat gland cells, 
and endothel ial cells; not shown) and transformed human cells 
(transformed amnion cells [AMA]) , HeLa, SV40-transformed 
keratinocytes (K14, Fig 3h), A431, A459, Molt-4, WISH, and 
W138-SV40) or in normal human fetal tissues analyzed so far ; 
these include adrenal g lands, hypophysis, lung, umbilical cord, ure-
ter, tongue, meninges, stomach, ear, pectoral muscle, kidney, 
brain, spleen, eye, mesonephric tissue, liver, pancreas, and thick in-
testine (results not shown). As far as we can judge from [32P]-ortho_ 
phosphate-labeling experiments, phorbolins are not phosphopro _ 
teins (compare Fig 4C and D). Whether a fraction of these proteins 
is phosphorylated is at present unknown and must await the prepa-
ration of specific antibodies to be used in immunoblotting experi-
nlents. 
The group of psoriasis- and PMA-upregulated proteins are not 
induced in SV40-transformed keratinocytes treated for 40 h with 
PMA (Fig 3h), suggesting that the effect may require the expression 
of a non transformed phenotype. Phorbolin 2 and MRP 14 are in-
duced in cultured human keratinocytes undergoing abnormal dif-
ferentiation [14] (Table I) but are on ly barely detected in non-cul-
tured human keratinocyte [1 4] populations containing a large 
proportion of normally differentiated cell s (Fig 1A). These observa _ 
tions indicate that the expression of this group of proteins is re lated 
to an abnormal differentiated phenotype, a characteristic of psoriatic 
keratinocytes. Furthermore, these proteins, IL-1 ra included, are not 
induced by PMA in normal human fibrobl as ts (Fig 4A,B) or T -lym-
phocytes (results not shown), hinting that the effect may be re-
stricted to epithelial cells. Further studies of epithelial cells other 
than keratinocytes may yield further information as to the specific-
ity of the phenomena. 
Obviously, psoriasis is a multifunctional disease in which in-
teractions between various signaling pathways may play a role 
in the disease [19] . From the experiments presented here we 
can so far infer that psoriatic keratinocytes exhibit an altered 
PKC signaling pathway. MOllse keratinocytes have been shown 
to express mHNAs encoding PKC-a, 0, E, " and I] [46] (L in hu-
mans) [47] and it is not possibl e at the moment to determine 
which of these isozyme(s) are affected in psoriasis. PKC isozyme 
appear to have distinct functio ns [48 ,49] and only a systematic study 
of these proteins and their regulation may shed some light on this 
problem. 
Experiments are currently underway to clone the gene coding for 
phorbolin 1 and to determine its functional activity. Because phor-
bolins show a high degree of specificity in their expression, interfer_ 
in g with their activity may lead to the development of drugs that 
may have therapeutic benefits in psoriasis. 
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Figure 4. IEF 2-0 gels of normal human fibroblasts and primary keratinocytes treated with PMA. (A) Control normal fi.broblasts; (BJ. PM A-treated normal 
human fibroblasts; (C) N ormal primary human kerat1l10cytes; fD) Nor~al pnmary human kerat1l10cytes treated with PMA. Primary normal human 
fibrob las ts were grown in OMEM containing 10% FCS andant~blOtlcs (pemc,1l1l1, 100 ul1lts/ml; streptomyc1l1, 50 ,ug/ml). Cells were treated for 20 h with 
pMA (100 ng/ ml) and labeled for 20 h with [35S]-methlonll1e 111 the presence of the phorbol ester. Samples were analyzed by IEF 2-0 gel electrophoresis 
followed by autoradiography. N ormal primary human keratinocytes were treated with PMA (100 ng/ml) for 20 h and labeled for 7 h with [32P]-orthophos-
phate in SFK.M lacking phosphate and containing the phorbol ester. Control kerat1l10cytes treated with equivalent amounts of OMSO used to dissolve the 
pMA were labeled for 7 h with [32P]-orthophosphate U1 the presence of OMSO. Samples were ana lyzed by IEF 2-0 gel electrophoresis followed by 
auto radiography. In (C) and (D) , one of two phosphorylated van ants of MRP14 IS llldicated. 
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